Azvudine is a thymus-homing anti-SARS-CoV-2 drug effective in treating COVID-19 patients
Jinlan Zhang(Chinese Academy of Medical Sciences & Peking Union Medical College), Jian‐Dong Jiang(Chinese Academy of Medical Sciences & Peking Union Medical College), Yong Liu(People's Hospital of Xinjiang Uygur Autonomous Region), Fengmin Shao(Heidelberg University), Qiangqian Zhang(Zhengzhou University), Xiaozhong Peng(Chinese Academy of Medical Sciences & Peking Union Medical College), Junbiao Chang(National Medical Products Administration), Jin‐Jin Cui(Chinese Academy of Medical Sciences & Peking Union Medical College), Yuhuan Li(Anhui Medical University), Hongqi Liu(Chinese PLA General Hospital), Suyun Li(Sun Yat-sen University), Peichun Sun(Henan Provincial People's Hospital), Ning Sheng(Chinese Academy of Medical Sciences & Peking Union Medical College), Shuaiyao Lu(Chinese Academy of Medical Sciences & Peking Union Medical College), Yuan-Hao Wan(Pingdingshan University), Yongsheng Che(Chinese Academy of Medical Sciences & Peking Union Medical College), Chen Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Ke Li(South China Agricultural University), Kun Wang(Air Force Engineering University), Lulu Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Rui Li(Max Planck Institute of Immunobiology and Epigenetics), Bin Liu(University of Minnesota), Chaoyang Wang(Zhejiang Cancer Hospital), Zhe Wang(University of Münster), Bo Zhu(Dalian Medical University), Zhenshun Cheng(Wuhan University), Limin Zhao(Zhengzhou University), Chunxia Ma(Chinese Academy of Medical Sciences & Peking Union Medical College), Shi‐Shan Yu(Chinese Academy of Medical Sciences & Peking Union Medical College)
Cited by 210
Related Papers
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
|The Lancet|2020|51.8k
RETRACTED: 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study
|The Lancet|2021|4.3k
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial
|The Lancet|2020|3.7k
A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version)
|Military Medical Research|2020|2.4k